CANDEL THERAPEUTICS, INC. - Common Stock, $0.01 par value (CADL)
CUSIP: 137404109
Q4 2021 13F Holders as of 31 Dec 2021
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 72,977,477
- Total 13F shares
- 6,951,728
- Share change
- +131,929
- Total reported value
- $54,359,000
- Price per share
- $7.82
- Number of holders
- 20
- Value change
- +$875,765
- Number of buys
- 13
- Number of sells
- 3
Quarterly Holders Quick Answers
What is CUSIP 137404109?
CUSIP 137404109 identifies CADL - CANDEL THERAPEUTICS, INC. - Common Stock, $0.01 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 137404109:
Top shareholders of CADL - CANDEL THERAPEUTICS, INC. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
3.4%
|
2,500,000
|
$27,100,000 | — | 30 Sep 2021 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.5%
|
1,125,000
|
$12,195,000 | — | 30 Sep 2021 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
1.1%
|
811,737
|
$8,799,000 | — | 30 Sep 2021 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.29%
|
213,580
|
$2,315,000 | — | 30 Sep 2021 | |
| Woodline Partners LP |
13F
|
Company |
0.14%
|
100,000
|
$1,084,000 | — | 30 Sep 2021 | |
| CAAS CAPITAL MANAGEMENT LP |
13F
|
Company |
0.07%
|
50,000
|
$542,000 | — | 30 Sep 2021 | |
| STATE STREET CORP |
13F
|
Company |
0.04%
|
26,600
|
$288,000 | — | 30 Sep 2021 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.03%
|
22,326
|
$242,000 | — | 30 Sep 2021 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.03%
|
20,395
|
$221,000 | — | 30 Sep 2021 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.01%
|
10,646
|
$115,000 | — | 30 Sep 2021 | |
| Udi Meirav |
3/4/5
|
Director |
—
class O/S missing
|
48,822
|
$43,940 | — | 26 Jul 2021 | |
| UBS Group AG |
13F
|
Company |
0%
|
3,000
|
$33,000 | — | 30 Sep 2021 | |
| SMITH ALAN E |
3/4/5
|
Director |
—
class O/S missing
|
32,548
|
$29,293 | — | 26 Jul 2021 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
1,054
|
$12,000 | — | 30 Sep 2021 | |
| Nathan Caffo |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
6,000
|
$5,400 | — | 29 Jul 2021 |
Institutional Holders of CANDEL THERAPEUTICS, INC. - Common Stock, $0.01 par value (CADL) as of Q4 2021
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2021 vs Q3 2021 Across Filers
| Investor | Q3 2021 Shares | Q4 2021 Shares | Share Diff | Share Chg % | Q3 2021 Value $ | Q4 2021 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.